Scipher Medicine is a precision immunology company matching patients with the most effective therapy.
Scipher Medicine holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data.
Scipher Medicine was founded in 2014 by Joe Loscalzo and Albert-Laszlo Barabasi. The company is headquartered in Waltham, Massachusetts.
Scipher leverages its proprietary Network Medicine platform and artificial intelligence, Spectra™, to commercialize blood tests revealing a persons’ unique molecular disease signature and match such signature to the most effective therapy, ensuring optimal treatment from day one.
Scipher is developing a patient molecular signature test, PrismRA®, ensuring rheumatoid arthritis patients are prescribed optimal targeted therapy from day one, and data collaborations to discover novel treatment targets based on their large and growing patient clinico-genomic database generated from tested patients.
Scipher is backed by Khosla Ventures, Cowen Healthcare Investments, Northpond Ventures, aMoon, Echo Health Ventures, Alumni Ventures, Neuberger Berman, Hitachi Ventures, and others. The company raised $110M in Series D round on Feb 24, 2022. This brings Scipher's total funding to $227M to date.